Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00357-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Lourdes Encinas und 18 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Isoniazid, Bacterial Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Isoniazid is an important first-line medicine to treat tuberculosis (TB). Isoniazid resistance increases the risk of poor treatment outcomes and development of multidrug resistance, and is driven primarily by mutations involving katG , encoding the prodrug-activating enzyme, rather than its validated target, InhA. The chemical tractability of InhA has fostered efforts to discover direct inhibitors of InhA (DIIs). In this study, we bridge the gap in understanding the potential contribution of DIIs to novel combination regimens and demonstrate a clear distinction of DIIs, like GSK693 and the newly described GSK138, from isoniazid, based on activity against clinical isolates and contribution to novel drug regimens. The results suggest that DIIs, specifically GSK138 and GSK693, could be promising partners in novel drug regimens, including those used against isoniazid-resistant TB, potentially enhancing their efficacy and/or preventing the selection of resistant mutants and supporting the continued exploration of InhA as a promising target for TB drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
- Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
- Discovery DMPK, GSK, Tres Cantos, Madrid, Spain.
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
- TB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
ORCID-Profile: Paul J Converse, David Barros-Aguirre, Eric L Nuermberger
Zitieren
APA
Encinas, L., Li, S. Y., Rullas-Trincado, J., Tasneen, R., Tyagi, S., Soni, H., Garcia-Perez, A., Lee, J., González Del Río, R., De Mercado, J., Sousa, V., Sosič, I., Gobec, S., Mendoza-Losana, A., Converse, P. J., Mdluli, K., Fotouhi, N., Barros-Aguirre, D., & Nuermberger, E. L. (2024). Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00357-24
Vancouver
Encinas L, Li SY, Rullas-Trincado J, Tasneen R, Tyagi S, Soni H, et al. Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00357-24
BibTeX
@article{Encinas2024,
author = {Encinas, Lourdes and Li, Si-Yang and Rullas-Trincado, Joaquin and Tasneen, Rokeya and Tyagi, Sandeep and Soni, Heena and Garcia-Perez, Adolfo and Lee, Jin and González Del Río, Rubén and De Mercado, Jaime and Sousa, Verónica and Sosič, Izidor and Gobec, Stanislav and Mendoza-Losana, Alfonso and Converse, Paul J and Mdluli, Khisi and Fotouhi, Nader and Barros-Aguirre, David and Nuermberger, Eric L},
title = {Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00357-24}
}
EUVIMED